Metformin and Nightly Fasting in Women With Early Breast Cancer
Phase 2
Recruiting
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Breast Ductal Carcinoma In SituInvasive Breast Carcinoma
- Interventions
- Procedure: Biospecimen CollectionDrug: Extended Release Metformin HydrochlorideOther: MonitoringOther: Nutritional AssessmentOther: Short-Term Fasting
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT05023967
- Locations
- 🇮🇹
Galliera Hospital, Genoa, Italy
🇮🇹European Institute of Oncology, Milano, Italy
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
Phase 1
Active, not recruiting
- Conditions
- Ann Arbor Stage III Marginal Zone LymphomaRefractory Follicular LymphomaAnn Arbor Stage III Grade 3 Follicular LymphomaRefractory High Grade B-Cell LymphomaRefractory Mantle Cell LymphomaAnn Arbor Stage III Grade 2 Follicular LymphomaAnn Arbor Stage IV Grade 3 Follicular LymphomaRefractory Aggressive B-Cell Non-Hodgkin LymphomaRefractory Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaAggressive B-Cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT05025800
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Sintilimab in Cancer of Unknown Primary
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT05024968
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Evaluating Shared Decision-Making for Lung Cancer Screening Among Chinese Populations in the United States
Withdrawn
- Conditions
- Cigarette Smoking-Related Carcinoma
- Interventions
- Procedure: DiscussionOther: Interview
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05024955
Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer
Not Applicable
Active, not recruiting
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8
- Interventions
- Procedure: DiscussionOther: Exercise InterventionOther: Informational InterventionOther: Medical Device Usage and EvaluationOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05025059
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
The Impact of COVID-19 on Pulmonary Procedures
Recruiting
- Conditions
- Hematopoietic and Lymphoid Cell NeoplasmCOVID-19 InfectionMalignant Solid Neoplasm
- Interventions
- Other: Survey Administration
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 250
- Registration Number
- NCT05022446
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study
Phase 1
Withdrawn
- Conditions
- Lung Non-Small Cell CarcinomaStage I Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8Stage IIA Lung Cancer AJCC v8Recurrent Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8
- Interventions
- Biological: Nivolumab
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05022394
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
Phase 2
Recruiting
- Conditions
- Metastatic OsteosarcomaLocally Advanced OsteosarcomaRefractory OsteosarcomaRecurrent OsteosarcomaUnresectable Osteosarcoma
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT05019703
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer
Phase 1
Active, not recruiting
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8
- Interventions
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT05017025
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study
Phase 2
Terminated
- Conditions
- Metastatic Undifferentiated Pleomorphic SarcomaLocally Advanced Undifferentiated Pleomorphic SarcomaRecurrent Undifferentiated Pleomorphic SarcomaUnresectable Undifferentiated Pleomorphic Sarcoma
- Interventions
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT05017103
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath